Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Glaukos Corporation heads into its October 28 earnings report with a contradictory setup: short interest has climbed 12% over the past month, the stock just posted its best daily gain of the quarter, and options traders are less defensive than they have been all year.
Short positioning has been rebuilding steadily. Short interest now stands at 7.6% of free float, up from around 6.7% a month ago, and the week-on-week change of roughly 4.9% marks one of the sharper acceleration points in the recent build. The borrow market, however, tells a very different story. Availability is extremely loose, with roughly 16 shares available to borrow for every one already lent out, and cost to borrow has actually eased this week to 0.38%, its lowest level in the 30-day window. That combination, rising short interest alongside cheap and plentiful borrow, points to deliberate new positioning rather than a forced unwind or a squeeze in the making. The ORTEX short score of 48.9 is mid-range and has only drifted modestly higher over the past two weeks, which is consistent with a measured build rather than a crowded pile-on.
Options positioning is the sharpest counterpoint to the short rebuild. The put/call ratio has dropped to 3.56, well below its 20-day average of 5.53, and is running about one standard deviation lighter on defensive positioning than recent norms. For context, the PCR touched 8.45 as recently as September 21, so the move lower is significant in pace if not in absolute level. Call volume has picked up relative to puts even as the stock gained 6.6% on Wednesday alone. That divergence between options and short interest is the central tension in the current setup: one cohort is adding shorts, while another is buying calls or simply not hedging.
The Street is broadly constructive, though the bull thesis carries a policy asterisk. Jefferies raised its target to $210 on September 22, maintaining a Buy, which puts it at the top of the range. Most analysts who updated after the July results moved targets higher, with clusters around $188 to $215 from Citigroup, Piper Sandler, Truist, and Stifel. UBS stands apart at Neutral with a $172 target, effectively flat with where the stock closed Wednesday. The consensus mean target of $199 implies roughly 15% upside from current levels. The bull case centres on iDose TR adoption momentum, with surveyed physicians expecting average procedure volumes to rise from 220 in 2024 to 290 in 2026, and on Epioxa as an emerging second growth leg. The bear case is a specific policy risk: proposed MAC LCD changes could require failed prior therapy before iDose TR use, which physicians estimate would reduce volumes by around 25%. That reimbursement overhang is the decisive variable the October print will need to address. Valuation is stretched, with a price-to-earnings multiple above 500x and an EV/EBITDA near 237x, both of which have eased from even higher levels over the past 30 days as earnings estimates have moved up.
The widest retail attention signal in the alt data is notable. Wikipedia pageviews for Glaukos are running more than five standard deviations above the prior 90-day average as of late September, the highest retail attention reading in the available data. None of the company's healthcare datasets have been measured to lead reported figures, so this is colour rather than a forward indicator, but the attention spike coincides with the stock's recent move and the ongoing policy debate around iDose reimbursement.
Insider activity is technically present but carries little signal weight. The Chief Development Officer has sold shares three times since mid-September, totalling around $250,000 in disclosed value, all under a pre-arranged 10b5-1 plan. The 90-day net insider position is negative at roughly 121,000 shares, but the dominant seller is one officer executing a scheduled programme, not a discretionary signal.
The October 28 print arrives 20 days from now, and the single most important disclosure will be any update on the proposed LCD process and its anticipated impact on iDose TR volumes, since that policy risk, not the underlying adoption trend, is what separates the bull and bear cases at this price.
See the live data behind this article on ORTEX.
Open GKOS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
